Multidrug resistance in prostate cancer

J P van Brussel1, G H J Mickisch

  • 1Department of Urology, Erasmus Medical Center Rotterdam, The Netherlands.

Onkologie
|May 29, 2003
PubMed

Insights

Multidrug resistance (MDR) mechanisms contribute to treatment failure in advanced hormone-refractory prostate cancer. Targeting these MDR pathways may improve therapeutic efficacy for this challenging disease.

Area of Science:

  • Oncology
  • Pharmacology
  • Cancer Biology

Background:

  • Advanced hormone-refractory prostate cancer presents a significant therapeutic challenge.
  • Current pharmaceutical treatments have not improved cancer-specific survival.
  • Chemotherapy failure may stem from multidrug resistance (MDR) mechanisms in cancer cells.

Purpose of the Study:

  • To investigate the involvement of MDR mechanisms in hormone-refractory prostate cancer.
  • To explore whether prostate cancer utilizes MDR principles against chemotherapeutic agents.

Main Methods:

  • Examination of diverse MDR pathways including MDR1, MRPs, glutathione, and apoptosis.
  • Assessment of these mechanisms in hormone-refractory prostate cancer in vitro and in vivo.

Main Results:

  • Evidence suggests the involvement of several MDR mechanisms in prostate cancer chemoresistance.
  • Functional expression of some MDR mechanisms, like MRP1, appears probable.
  • MDR pathways are partially established to varying degrees in this cancer type.

Conclusions:

  • Multidrug resistance mechanisms play a role in the chemoresistance of hormone-refractory prostate cancer.
  • Reversing, circumventing, or overcoming MDR pathways offers potential for improved treatment efficacy.
  • Targeting MDR pathways may provide new therapeutic avenues for intractable prostate cancer.

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...